LA JOLLA, Calif., Sept. 16, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, announced today that its common stock has been approved for quotation on the OTCQB® marketplace in the United States under the symbol "KURO".
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura's diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. The company's lead drug candidate is tipifarnib, a farnesyl transferase inhibitor that is currently in a Phase 2 clinical study in patients with locally advanced tumors that carry HRAS mutations. The company's preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL inhibitor program. More information about Kura Oncology may be found at www.kuraoncology.com.
CONTACT: INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 email@example.com MEDIA CONTACT: Mark Corbae Vice President Canale Communications (619) 849 5375 firstname.lastname@example.org